Welcome to our dedicated page for Cutera news (Ticker: CUTR), a resource for investors and traders seeking the latest updates and insights on Cutera stock.
The CUTR news page on Stock Titan aggregates historical and restructuring-related news for Cutera, Inc., a company focused on aesthetic and dermatology solutions within the surgical and medical instrument manufacturing sector. Company releases describe Cutera as a provider of energy-based medical aesthetic technologies for practitioners worldwide, with more than 25 years of activity in the medical aesthetics field.
News coverage for CUTR includes financial performance updates, such as quarterly results that break out product and service revenue, trends in capital systems sales, recurring revenue, and cash balances. These reports also describe cost restructuring programs, non-GAAP financial measures, and changes in operating expenses, offering insight into how the business has managed its cost structure and profitability goals over time.
Another major category of news involves capital structure and corporate transformation. In 2025, Cutera announced a pre-packaged Chapter 11 restructuring supported by existing lenders, with plans to reduce debt and raise new financing. Subsequent releases detailed its intention to voluntarily delist its common stock from the Nasdaq Global Select Market, suspend SEC reporting obligations through a planned Form 15 filing, and ultimately emerge from Chapter 11 as a private company backed by a consortium of investment firms.
Product and partnership announcements also appear in the CUTR news flow. Examples include updates on AviClear, described as a breakthrough technology for acne treatment, and truFlex® muscle stimulation, as well as an exclusive distribution agreement through Cutera KK to promote and distribute select SkinCeuticals® products to medical and physician-led clinics in Japan. Cutera has also highlighted collaborations such as its partnership with the Adaptive Training Foundation to provide truFlex treatments to adaptive athletes.
By reviewing the CUTR news archive, users can trace how Cutera communicated its business performance, product developments, partnerships, restructuring steps, and transition from a publicly traded company to a privately held entity. This makes the news page a useful resource for understanding the company’s historical trajectory and the events that shaped its capital structure and market presence.
Cutera, Inc. (NASDAQ: CUTR) announced plans to offer $100 million in convertible senior notes due 2029 to qualified institutional buyers. The offering may include an additional $20 million at the initial purchasers' option. Proceeds will cover the costs of capped call transactions and fund general corporate purposes, including working capital, acquisitions, and potential stock repurchases. The notes are unsecured and will be convertible into cash or common stock. Notably, this offering aims to mitigate potential dilution of shares upon conversion.
Cutera, Inc. (CUTR) announced its response to a recent FDA inquiry regarding marketing materials related to its MyJuliet device. The company had previously removed all materials related to gynecological uses in 2019. However, a vestigial marketing piece was recently identified in an FDA Warning Letter, attributed to a third-party website that Cutera managed. Cutera is taking corrective actions to ensure compliance and has not promoted MyJuliet since 2019, with minimal sales. The company intends to exit this market segment while supporting its customers and complying with FDA guidance.
Cutera, Inc. (CUTR), a prominent provider of aesthetic and dermatology solutions, announced that CEO Dave Mowry and VP Greg Barker will speak at the Piper Sandler 34th Annual Healthcare Conference. The event is scheduled for November 30, 2022, at 2:00 PM ET, and will take place at the Lotte New York Palace Hotel in New York, NY. The session will also be available via webcast on Cutera's website, with a replay provided approximately one hour after the event concludes.
Cutera, Inc. (NASDAQ: CUTR) announced participation in a fireside chat at the Stephens Annual Investment Conference. CEO Dave Mowry and VP Greg Barker will speak on November 16, 2022, at 4:00 pm CT in Nashville, TN. Interested parties can access the live webcast through the Investor Relations section of Cutera's website, with a replay available one hour after the event concludes.
Based in Brisbane, California, Cutera specializes in aesthetic and dermatology solutions, providing innovative products since 1998.
Cutera, Inc. (CUTR) will participate in a fireside chat at the Stifel Healthcare Conference on November 15, 2022, at 8:00 am ET. The event will feature CEO Dave Mowry and Executive Chairperson J. Daniel Plants, providing insights into the company's aesthetic and dermatology solutions. Attendees can access the live webcast via Cutera's Investor Relations page, with a replay available one hour post-event. Headquartered in Brisbane, California, Cutera has been a leader in innovative dermatological products since 1998.
Cutera, Inc. (NASDAQ: CUTR) announces the extensive launch of AviClear, the first FDA-cleared and Health Canada-approved device for treating acne. The product has gained significant traction since its FDA clearance in March 2022, receiving the 'Best Laser Treatment for Acne' award from Cosmopolitan Magazine. A new financing option is available for US consumers starting at $99/month. CEO Dave Mowry expressed confidence in growing patient demand, aiming to establish AviClear as the gold standard in acne treatment.
Cutera, Inc. (Nasdaq: CUTR) reported Q3 2022 revenue of $62.8 million, marking a 9% year-over-year increase. Capital equipment sales grew 27%, while consumable product revenue surged 66%. Despite a GAAP net loss of $12.1 million, the company reiterated its 2022 revenue guidance of $255 million to $260 million, driven by strong demand for its products and a full launch of AviClear in North America. The company faced foreign exchange headwinds of approximately $17 million but expects constant currency growth of 18-20% for the year.
Cutera, Inc. (CUTR) presented positive 12-month clinical data for AviClear at the Annual Fall Clinical Dermatology Conference held from October 20-23 in Las Vegas. The data indicates that after three treatment sessions, 92% of patients experienced visible improvement in acne after 12 months. Additionally, three-fourths of participants showed significant improvement, and two-thirds were assessed as clear or almost-clear. AviClear, the only FDA-cleared device for acne treatment, aims to provide an alternative to isotretinoin. The findings support the device's long-term effectiveness and safety.
Cutera, Inc. (CUTR) will announce its Q3 2022 financial results on November 3, 2022, after market close, followed by a conference call at 1:30 p.m. PT (4:30 p.m. ET). Interested parties can join the call by calling 1-800-319-4610 domestically or +1-631-891-4304 internationally, or via webcast on their website. Cutera specializes in aesthetic and dermatology solutions since 1998, providing innovative and effective treatment options worldwide.
Cutera, Inc. (CUTR) reports significant adoption of its AviClear laser treatment, with over 1,000 procedures performed since its launch in April 2022. This device is the first FDA-cleared option for treating all severities of acne. Recently, AviClear also gained approval from Health Canada. About 90% of patients showed visible improvement after treatment, scoring 4.9 out of 5 for satisfaction. CEO David Mowry noted unprecedented speed in physician adoption and patient interest, underscoring AviClear's impact in modern skincare.